Jayson Rieger - 14 Mar 2025 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
CEO and President, Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
VRCA
Transactions as of
14 Mar 2025
Net transactions value
$0
Form type
4
Filing time
18 Mar 2025, 18:45:07 UTC
Previous filing
26 Nov 2024
Next filing
25 Nov 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Employee Stock Option (right to buy) Award $0 +850,000 $0.000000 850,000 14 Mar 2025 Common Stock 850,000 $0.8900 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/8th of the total shares subject to the option shall vest on September 14, 2025, and 1/48th of the total shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continuous service through such vesting date.